Evidence map›Paper›PMID 36463568›Full record

ArticleInternational journal of hematology2023

Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy.

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Yen-Lin Liu, Jia-Ruey Tsai, Chen-Hua Tsai, Chao-Neng Cheng, Yeu-Chin Chen

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Contemporary approaches to treat people with hemophilia: what's new and what's not?Research and practice in thrombosis and haemostasis · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chia-Yau ChangDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Shiue-Wei LaiDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No.325, Section 2, Chenggong Road, Nei-Hu 114, Taipei, Taiwan.
Mei-Mei ChengDepartment of Pediatrics, Cheng Hsin General Hospital, Taipei, Taiwan.
Jung-Tzu KuDepartment of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan.
Shu-Hsia HuHemophilia Center, Taipei Medical University Hospital, Taipei, Taiwan.
Yen-Lin LiuDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Jia-Ruey TsaiHemophilia Center, Taipei Medical University Hospital, Taipei, Taiwan.
Chen-Hua TsaiHemophilia Center, Taipei Medical University Hospital, Taipei, Taiwan.
Chao-Neng ChengDivision of Pediatric Hematology/Oncology, Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.
Yeu-Chin ChenDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No.325, Section 2, Chenggong Road, Nei-Hu 114, Taipei, Taiwan. yeuchin99@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecombinant factor VIII-Fc (rFVIIIFc) became available in Taiwan in 2018. Before this date, no people with hemophilia A (PwHA) were enrolled in a clinical trial of rFVIIIFc. We investigated changes in bleeding outcomes and product utilization in PwHA switching from rFVIII to rFVIIIFc.

methodsData were collected for Taiwanese PwHA (severe-type) who switched from rFVIII to rFVIIIFc, including annualized bleeding rate (ABR) and weekly dose consumption 12 months pre-switch and > 6 months post-switch.

resultsThe 51 patients were divided into 3 groups according to their pre-switch treatment: on-demand treatment, intermittent periodic prophylaxis, and regular prophylaxis. In every group, the post-switch median ABR was significantly reduced, with no significant differences between groups. Meanwhile, the post-switch median weekly dose of each group was significantly increased. In 32 patients on pre-switch prophylaxis, switching brought a further reduction in median ABR, associated with a significant increase in median weekly dose. No adverse effects or novel inhibitor development were seen.

conclusionThis is the first report from Asia on real-world experience of rFVIIIFc, showing that switching to rFVIIIFc prophylaxis led to further reduction in ABR and increase in weekly dose for all patient groups, even those on pre-switch rFVIII prophylaxis.

Indexed as

Hemophilia AFactor VIIIHalf-LifeHemorrhageHumansImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsTreatment OutcomeFactor VIIIImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAnnualized bleeding rateFactor utilizationHemophilia AProduct switchingrFVIIIFc

Identifiers

PMID36463568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.